Iovance Biotherapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission inv...
Latest News
16 hours ago · marketbeat.com
Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales ClimbIovance Biotherapeutics NASDAQ: IOVA is preparing to seek a lung cancer indication for its cell therapy AMTAGVI in 2027 while expanding its melanoma treatment network and advancing studies in earlier-stage melanoma and rare sarcomas, executives said at a Jefferies event.
23 hours ago · seekingalpha.com
Iovance: The Lung Selloff Went Too Far For A Business Growing 77%Iovance's Amtagvi had its best quarter, at $101.60 million, up 77%, and operating cash burn nearly stopped at -$4.47 million. Proleukin did half of the sequential jump. The lung update sank the stock 47.60% from October 28. Outside a subgroup drawn after the data came in, the response was 8.51%, below the 12.8% Iovance cites for docetaxel. My sum-of-the-parts rNPV for IOVA gives a fair value of $8.86 in the base case and $13.32 if Amtagvi beats its own target, against a price of $7.76.
4 days ago · globenewswire.com
Iovance Biotherapeutics to Present at Upcoming ConferencePHILADELPHIA, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conference: 2026 Jefferies Global Healthcare Conference in LondonFireside Chat: November 16, 2026, at 11:00 a.m. GMT / 6:00 a.m.
11 days ago · zacks.com
IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D CostsIovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.
11 days ago · seekingalpha.com
Iovance Q3 Earnings: Why I'm Reiterating My Buy Call Despite Market ReactionIovance Biotherapeutics, Inc., delivered strong Q3 results, with revenues up ~80% YoY and gross margin rising to 60%. IOVA reaffirmed 2026 guidance of $410–$420M revenue, and maintains a robust cash position ($376M) expected to last into 2029. Amtagvi's market-leading durability and expanding treatment center network support its competitive positioning despite intense oncology competition.
11 days ago · seekingalpha.com
Iovance: Reset Expectations Make The Stock A Buy Again (Rating Upgrade)Iovance Biotherapeutics, Inc. fell 46% after my downgrade to Hold in September, reflecting over-optimism in valuation. AMTAGVI's (lifileucel) melanoma launch gained momentum, but the NSCLC opportunity appeared overestimated based on Q2 call signals. Recent NSCLC data showed a 24.6% ORR across 69 evaluable patients, slightly below the prior interim readout.
11 days ago · zacks.com
IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline ProgressIovance reaffirms its 2026 revenue outlook as Q3 sales jump 80%, fueled by Amtagvi adoption, improving margins and progress in its cancer pipeline.
11 days ago · seekingalpha.com
Iovance Biotherapeutics, Inc. (IOVA) Q3 2026 Earnings Call TranscriptIovance Biotherapeutics, Inc. ( IOVA ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Jen Saunders Frederick Vogt - Interim CEO, President, General Counsel, Corporate Secretary & Director Corleen Roche - Chief Financial Officer Daniel Kirby - Chief Commercial Officer Noah Berkowitz - Chief Medical Officer Raj Puri - Chief Regulatory Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Etzer Darout - Barclays Bank PLC, Research Division Kuan-Hung Lin - Wells Fargo Securities, LLC, Research Division Nicholas Lorusso - TD Cowen, Research Division Joshua Korsen - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Welcome to the Iovance Biotherapeutics Third Quarter 2026 Conference Call.
11 days ago · marketbeat.com
Iovance Biotherapeutics Q3 Earnings Call HighlightsIovance Biotherapeutics NASDAQ: IOVA reported record third-quarter revenue of approximately $122 million, up 80% from a year earlier, as sales of its melanoma treatment AMTAGVI surpassed $100 million in a quarter for the first time.
12 days ago · zacks.com
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue EstimatesIovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.25 per share a year ago.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove IOVA